Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Elucidating the mechanisms underlying KRT19 contributes to NSCLC progression [PC-9 cells_RNA-Seq]

ABSTRACT: As a member of the acidic type I cytokeratin family, keratin 19 (KRT19) is originally known to form the intermediate filament cytoskeleton and responsible for structural rigidity and multipurpose scaffolds.KRT19 is abnormally expressed in various cancers including hepatocellular carcinoma, breast cancer,serous ovarian cystadenocarcinoma and et.al. KRT19 has been revealed to mediate cell cycle arrest, cancer stem cell reprogramming by interacting with cellular molecules including receptors, adaptors, effectors and kinases. Increasing evidence illustrates the clinical significance of KRT19 in lung cancer, extensive studies are urged to elucidate the role and underlying mechanism of KRT19 in NSCLC progression, we performed RNA-Seq to identify its target genes in PC-9 cell lines.

ORGANISM(S): Homo sapiens

PROVIDER: GSE299060 | GEO | 2026/01/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Elucidating the mechanisms underlying KRT19 contributes to NSCLC progression

Project description:As a member of the acidic type I cytokeratin family, keratin 19 (KRT19) is originally known to form the intermediate filament cytoskeleton and responsible for structural rigidity and multipurpose scaffolds.KRT19 is abnormally expressed in various cancers including hepatocellular carcinoma, breast cancer,serous ovarian cystadenocarcinoma and et.al. KRT19 has been revealed to mediate cell cycle, cancer stem cell reprogramming by interacting with cellular molecules including receptors, adaptors, effectors and kinases. Increasing evidence illustrates the clinical significance of KRT19 in lung cancer, extensive studies are urged to elucidate the role and underlying mechanism of KRT19 in NSCLC progression, we performed RNA-Seq to identify its target genes in A549 cell lines.

2026-01-21 | GSE298926 | GEO

Elucidating the mechanisms underlying KRT19 contributes to NSCLC progression [PC-9 cells_RNA-Seq]

Project description:Elucidating the mechanisms underlying KRT19 contributes to NSCLC progression [PC-9 cells_RNA-Seq]

| PRJNA1272490 | ENA

Elucidating the mechanisms underlying KRT19 contributes to NSCLC progression

Project description:Elucidating the mechanisms underlying KRT19 contributes to NSCLC progression

| PRJNA1271941 | ENA

Signal peptide-independent secretion of keratin-19 by pancreatic cancer cells

Project description:T cells exclusion precludes checkpoint inhibition efficacy in pancreatic ductal adenocarcinoma (PDA) and is mediated by the interaction between T cell CXCR4, and its ligand CXCL12, which is complexed to keratin-19 (KRT19) on the surface of PDA cells. KRT19 secretion is essential to this process but is unusual because KRT19 lacks an endoplasmic reticulum (ER)-directing signal peptide (SP). By using ER-restricted TurboID sys-tems and a split-GFP assay, we demonstrate that KRT19 enters the ER via its “head” domain. In vivo, tumors formed with ER-TurboID cells contain biotinylated KRT19. Additionally, KRT19 is shown to interact with the sig-nal recognition particle and its secretion is sensitive to canonical protein secretion inhibitors. Although keratin-8 (KRT8) co-localizes with KRT19 on the surface of PDA cells, KRT8 does not enter the ER. However, both keratins are externalized via secretory autophagy. Thus, despite lacking a classical SP, PDA cells secrete KRT19 to protect against immune attack.

2025-06-16 | PXD051583 | Pride

Transcription profiling of mouse transgenic tumors driven by Her or Ras

Project description:previously published mouse data; Pubmed IDS: 12754511, 12839964 Experiment Overall Design: see Black, EP, et.al., Cancer Res. 2003 Jul 1;63(13):3716-23 and Huang, E., et.al. Nat Genet. 2003 Jun;34(2):226-30.

2008-06-12 | E-GEOD-3158 | biostudies-arrayexpress

Project description:Background: Tissue kallikrein-related peptidases 4, 5, 6 and 7 (KLK4-7) strongly increase the malignancy of ovarian cancer cells. By further deciphering the downstream effectors of KLK4-7, we aimed at finding new potential prognostic biomarkers and treatment targets for ovarian cancer patients. KLK4-7-transfected and vector-control OVMZ-6 (OV-KLK4-7 and OV-VC) ovarian cancer cells were established to select differentially regulated factors. Methods: Three independent approaches, PCR arrays, genome-wide microarray and proteome analyses, were pursued leading to the identification of ten candidates (MSN, KRT19, COL5A2, COL1A2, BMP5, F10, KRT7, JUNB, BMP4, MMP1). Differential gene expression in OV-KLK4-7 versus OV-VC cells was validated by qPCR. To determine differential protein expression, Western blot analyses, immunofluorescence and immunohistochemistry were applied for four candidates (MSN, KRT19, KRT7, JUNB) in both cell lines and tumor xenografts. Results: These experiments demonstrated that KLK4-7 distinctly regulate expression of MSN, KRT19, KRT7 and JUNB on the mRNA and protein levels in ovarian cancer cells and tissues. Protein expression of the top upregulated effectors, MSN and KRT19, was investigated by immunohistochemistry in a cohort of patients (n=66) afflicted with high-grade serous ovarian cancer and related to the immuno-expression levels of KLK4-7. Significant positive associations were found for KRT19/KLK4 (P=0.010), KRT19/KLK5 (P=0.030) and MSN/KLK7 (P=0.001); KRT19 and MSN immuno-expression showed a trend towards significance with KLK6. Conclusions: These findings imply that KLK4-7 exert key modulatory effects on other cancer-related genes and proteins in ovarian cancer. The key downstream effectors of KLK4-7, MSN and KRT19, may represent important therapeutic targets associated with serous ovarian cancer.

2018-12-26 | GSE109261 | GEO

The immunological comparison of control PDA tumors and Krt19-edited PDA tumors

2022-01-07 | GSE193027 | GEO

Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial transitional cell carcinomas

Project description:The mammalian ureter contains a water-tight epithelium surrounded by smooth muscle. Key molecules have been defined which regulate ureteric bud initiation and drive the differentiation of ureteric mesenchyme into peristaltic smooth muscle. Less is known about mechanisms underlying the developmental patterning of the multilayered epithelium characterising the mature ureter. In skin, which also contains a multilayered epithelium, cytokeratin 15 (CK15), an intermediate filament protein, is a marker for cells whose progeny contribute to epidermal regeneration following wounding. Moreover, CK15+ precursor cells in skin can give rise to basal cell carcinomas. In the current study, using transcriptome microarrays of embryonic wild type mouse ureters, we detected Krt15, coding for CK15.

2013-12-01 | E-MEXP-3929 | biostudies-arrayexpress

Transcription profiling of human growing breast cancer cell lines

Project description:Gene expression analysis on growing breast cancer cell lines. Experiment Overall Design: see Bild, A. et.al.

2008-06-12 | E-GEOD-3156 | biostudies-arrayexpress

The immunological comparison of control PDA tumors and Krt19-edited PDA tumors

Project description:Our studies indicate that cancer cells of carcinomas are coated with CXCL12 chemokine in covalent conjugation with keratin-19 (KRT19). Murine pancreatic ductal adenocarcinomas (PDA) formed with Krt19-edited cancer cells lack the CXCL12-coating and are infiltrated with T cells, compared to tumors formed with control sgScramble PDA cells. To probe the immunological role of this CXCL12-coating thoroughly, bulk RNA sequencing of subcutaneous (s/c) murine sgScramble PDA tumors and Krt19-edited PDA tumors were conducted. As comparison, an immunogenic tumor model was also assessed. To do so, s/c sgScramble PDA tumors and PDA tumors formed with sgScramble cells exppressing doxcycline-inducible ovalbumin (icOVA) were harvested and processed for bulk RNA sequencing.

2022-01-04 | GSE192853 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data